bioAffinity Technologies, Inc. (BIAF) intrinsic value & 10-year financials
bioAffinity Technologies, Inc. (BIAF) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 986.6% a year to $6.2M, with an average return on invested capital of -189.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.73
- Market cap
- $6.4M
- Revenue (FY2025)
- $6.2M
- Revenue growth (6-yr CAGR)
- 986.6%
- ROIC (10-yr avg)
- -189.8%
- Free cash flow (FY2025)
- -$9.4M
BIAF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $6.2M | -$14.9M | -$8.66 | -$9.4M | -171.6% | -549.7% |
| FY2024 | $9.4M | -$9.0M | -$0.75 | -$7.3M | -95.6% | -329.4% |
| FY2023 | $2.5M | -$7.9M | -$0.91 | -$6.1M | -314.8% | -252.9% |
| FY2022 | $4.8K | -$8.2M | -$0.91 | -$4.3M | -83511.5% | 169.0% |
| FY2021 | — | -$6.3M | — | — | — | 14.3% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
bioAffinity Technologies, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
bioAffinity Technologies, Inc. has historically struggled to out-earn its cost of capital, averaging just 0.9% ROIC.
bioAffinity Technologies, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, bioAffinity Technologies, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-287.65 per share.